Cellink has announced the commencement of trading in the company’s shares on Nasdaq Stockholm Main Market.
“I would like to begin by thanking the entire Cellink team, the board of directors, investors, and, above all, our customers for their continued trust and for their amazing work. This exciting journey started by four pioneers just four years ago and has now matured to a multinational company operating in six countries, with 200 brilliant employees, installations in more than 55 countries around the world, and is now listed on Nasdaq Stockholm Main Market. It is with tremendous pride, honor, and confidence that we look into the future entering into a new chapter for Cellink, following the vision of changing the future of medicine as we know it,” says Erik Gatenholm, CEO of Cellink.
Cellink’s shares will continue to be traded under the same ticker (CLNK B) and ISIN code (SE0013647385). No new shares will be issued in connection with the listing. Shareholders of CELLINK do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market.
Photo: Erik Gatenholm, CEO, Gusten Danielsson, CFO and Hector Martinez, CTO, of Cellink